Clinical trials: Abuse Liability
Electronic Cigarette Use
Effects of Electronic Cigarette Flavors on Abuse Liability in Smokers (P3-Taste)
The purpose of this study is to determine if abuse liability indices will be impacted by varying flavors and e-cigarette (ECIG) nicotine delivery capability (i.e., nicotine flux) among current combustible cigarette users.
- Trial name
- NCT05971823
- Testing
- Tobacco product administration and assessment
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Opioid Abuse
Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse
The purpose of this study is to assess the abuse liability of 4 times (8 tablets) the usual recommended dose of Acurox (oxycodone HCl 40 mg plus niacin 240 mg) versus oxycodone HCL 40 mg alone in subjects with a history of opioid…
- Trial name
- NCT00699010
- Testing
- Acurox 5/30mg taken first, Oxycodone 5mg taken first
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Acura Pharmaceuticals Inc.
Nicotine Dependence
Pharmacokinetics, Subjective Effects, and Abuse Liability of Nicotine Salt-Based Vaping Products With Tobacco or Unflavored E-liquids, SALTVAPE Study
This trial studies activity of time (pharmacokinetics), subjective effects, and abuse liability of nicotine salt-based vaping products with tobacco or e-liquids.
- Trial name
- NCT04231539
- Testing
- Nicotine, Vaporizer Device, Salt-HIgh Nicotine Unflavored (Product B)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Roswell Park Cancer Institute
Abuse Liability of Staccato Alprazolam
Staccato Alprazolam Abuse Liability
Compare the abuse liabilities of Staccato Alprazolam, oral immediate-release alprazolam, and Staccato Placebo.
- Trial name
- NCT00603980
- Testing
- Inhaled alprazolam 0.5 mg, Inhaled alprazolam 1 mg, Inhaled alprazolam 2 mg
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Nova Pneuma Inc.
Abuse Potential
Study Evaluating Abuse Potential of Lyrica® in Healthy Non-Drug Dependent Recreational Opioid Users
This is a Phase 4 clinical study in healthy non-drug dependent recreational opioid users to assess the abuse potential of Lyrica when taken alone or in combination with oxycodone.
- Trial name
- NCT05053126
- Testing
- Pregabalin 300mg, pregabalin 450 mg, Pregabalin 300 mg with oxycodone 20 mg
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Viatris Specialty LLC
Tobacco Use
The Abuse Liability of a Novel Heated Tobacco Product (IQOS) and Its Feasibility as a Menthol Cigarette Substitute
This project examines the influence of flavor availability on switching to an MRTP known as IQOS, part of the Heated Tobacco Product (HTP) class, among menthol smokers using clinical lab and naturalistic evaluations of abuse…
- Trial name
- NCT05499377
- Testing
- Tobacco product administration and assessment
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Opioid-Related Disorders, Substance-Related Disorders
Prescription Opioid Effects in Abusers Versus Non-Abusers
The purpose of this study is to examine the abuse liability of oxycodone in individuals with, and without, a history of prescription opioid abuse.
- Trial name
- NCT00158184
- Testing
- oxycodone 15 mg, oxycodone 30 mg
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Substance-Related Disorders
Abuse Liability of Reduced Nicotine Content Cigarettes Within a Complex Tobacco Marketplace
Tobacco regulatory policies can have unanticipated consequences; therefore, methods that would permit prospective estimates of the effects of potential tobacco regulations are necessary for the development of tobacco regulatory…
- Trial name
- NCT02951143
- Testing
- SPECTRUM cigarettes, SPECTRUM cigarettes between
- Where
- United States
- Volunteers
- 305 people, healthy volunteers welcome
- Sponsor
- Virginia Polytechnic Institute and State University
Cannabis, Pain
Repeated Cannabis Administration on Experimental Pain and Abuse Liability
Chronic pain is a significant public health concern in the U.S., for which prescription opioids have historically been the standard treatment. This has resulted in striking rates of opioid use disorders and fatal overdoses.
- Conditions
- Cannabis, Pain, Tolerance, Hyperalgesia
- Trial name
- NCT04576507
- Testing
- Active Cannabis
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Tobacco Use
Sugars in Cigarettes
The aim of this study is to investigate the impact of sugar levels in cigarette tobacco on cigarette abuse liability and appeal.
- Trial name
- NCT05308316
- Testing
- Cigarettes with added sucrose
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Masonic Cancer Center, University of Minnesota
Opioid Abuse
Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users
The primary objective of this study is to compare the relative abuse potential of two different doses of orally administered Acurox Tablets to orally administered immediate-release (IR) oxycodone HCl tablets in non-dependent…
- Trial name
- NCT01030406
- Testing
- 40/0mg taken first, 80/0mg taken first, 40/240mg taken first
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Acura Pharmaceuticals Inc.
Healthy
A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers
The main purpose of this study is to determine if oxycodone and naltrexone combination capsules (ALO-02) have the potential to be abused.
- Trial name
- NCT01746901
- Testing
- intact ALO-02 60 mg/7.2 mg, crushed ALO-02 60 mg/7.2 mg, crushed oxycodone IR 60 mg
- Where
- Canada
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Pfizer
Abuse Potential
Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience
This will be a randomized, double-blind, double-dummy, placebo- and active controlled, 5 treatment, 10 sequence, 5 period crossover single dose, Williams square design study in healthy adult, non drug dependent male and female…
- Trial name
- NCT04570436
- Testing
- gabapentin 600 mg, gabapentin 1200 mg, gabapentin 1800 mg
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Viatris Specialty LLC
Nondependent Opioid Abuse, Episodic
Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users
The primary purpose of this study is to determine the abuse potential of EMBEDA compared to controlled release morphine when crushed and taken orally by non-dependent recreational opioid users; secondary purposes include to…
- Trial name
- NCT01380093
- Testing
- MS Contin (morphine sulfate, controlled release), EMBEDA (morphine sulfate / naltrexone hydrochloride)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Users When ALO-02 Capsules Are Crushed and Snorted
The main purpose of this study is to determine if oxycodone and naltrexone combination capsules (ALO-02) have the potential to be abused when they are crushed and snorted.
- Trial name
- NCT01775189
- Testing
- crushed ALO-02 30 mg/3.6 mg, crushed oxycodone IR 30 mg
- Where
- Canada
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Pfizer
Heroin Dependence, Nicotine Dependence
Pioglitazone for Heroin and for Nicotine Dependence
The goal of the proposed research is to improve the effectiveness of treatments for opioid and for nicotine dependence by testing a novel pharmacological strategy.
- Trial name
- NCT01395797
- Testing
- PIO
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Opioid Abuse
Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone
The ability of pioglitazone (PIO) to alter the effects of opioids in humans has not been characterized in a controlled laboratory setting.
- Trial name
- NCT01395784
- Testing
- pioglitazone
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Abuse Potential
Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users
This will be a randomized, double-blind, double-dummy, placebo- and active-controlled, 6 treatment, 6-period crossover single-dose, Williams square design study in healthy male and/or female adult, non-drug-dependent recreational…
- Trial name
- NCT05319756
- Testing
- gabapentin 600 mg, gabapentin 1200 mg, gabapentin 600 mg and oxycodone HCl 20 mg
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Viatris Specialty LLC
Electronic Nicotine Delivery System Flavors
Potential Effects of Electronic Nicotine Delivery System Flavor Regulations on African American Menthol Smokers
This study aims to better understand how the availability of electronic nicotine delivery system (aka electronic cigarettes) flavors (e.g., menthol, tobacco) impacts tobacco use behaviors, toxicant exposure, and abuse liability…
- Trial name
- RVA Flavors (NCT05023096)
- Testing
- Tobacco product administration and assessment
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Opioid-related Disorders
Abuse Liability of Suboxone Versus Subutex
The study is designed to compare the abuse liabilities of intravenous buprenorphine and buprenorphine/naloxone in individuals who are physically dependent on sublingual buprenorphine.
- Trial name
- NCT00710385
- Testing
- Heroin, Naloxone, Low Bup Dose
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute